PSNL
PersonalisยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
PSNL Profile
Personalis, Inc.
A leading provider of advanced genomics and AI-powered precision medicine solutions for cancer and rare genetic disorders
Life Science Tools and Services
02/21/2011
06/20/2019
NASDAQ Stock Exchange
228
12-31
Common stock
6600 Dumbarton Circle, Fremont, California 94555
--
Personalis, Inc., was incorporated in Delaware on February 21, 2011 and commenced operations in September 2011. The company is a growing cancer genomics company that transforms the development of next-generation therapies by providing more comprehensive molecular data on each patient's cancer and immune response. The company designs its NeXT platform to accommodate the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all approximately 20,000 human genes as well as the immune system, while many cancer groups cover approximately 50 to 500 genes. They are also developing a supplementary liquid biopsy analysis that analyzes all human genes with the more focused liquid biopsy analysis currently available. By combining technological innovation, operational scale and regulatory differentiation, their NeXT platform is designed to help their clients gain new insights into treatment response and resistance mechanisms as well as new potential treatment targets.
